Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2007-01-23

AUTHORS

N Starling, D Tilden, J White, D Cunningham

ABSTRACT

The treatment of colorectal cancer is rapidly becoming a significant financial burden to health-care systems within economically developed nations. A current challenge for oncologists and health-care payers is to integrate new, often high-cost, biologic therapies into clinical practice. Inherent to this process is the consideration of cost-effectiveness. The aim of this study was to compare the cost-effectiveness of cetuximab plus irinotecan with an appropriate comparator from a National Health Service (NHS) perspective. This economic evaluation is a trial-based study of cetuximab vs active/best supportive care. Effectiveness estimates for the treatment groups were modelled from key clinical trials. Cunningham et al (2004) compared cetuximab/irinotecan with cetuximab monotherapy; Cunningham et al (1998) compared irinotecan monotherapy in a second-line setting with supportive care. Modelling was necessary owing to an absence of head-to-head clinical trial data of cetuximab/irinotecan vs current standard care. Costs were calculated for the study drugs received, associated administration, palliative chemotherapy for patients in the standard care arm and other nonchemotherapy resources. The discounted life-expectancy of patients treated with cetuximab/irinotecan was 0.91 life-years, and 0.47 discounted life-years for patients receiving active/best supportive care. Patients treated with cetuximab/irinotecan accumulated mean additional costs of £18 901 per patient relative to the comparator arm, with £11 802 attributable to cetuximab. The incremental cost per life-year gained with cetuximab/irinotecan therapy compared with active/best supportive care was £42 975. The incremental cost per quality adjusted life-year gained was £57 608. The incremental cost per life-year gained for cetuximab/irinotecan is relatively high compared with other health-care interventions. However, this result should be considered in the context of a number of factors specific to the treated patient population. More... »

PAGES

206-212

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.bjc.6603561

DOI

http://dx.doi.org/10.1038/sj.bjc.6603561

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1028751386

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/17242694


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Camptothecin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cetuximab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colorectal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Irinotecan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Salvage Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Royal Marsden Hospital, Sutton, Surrey, UK", 
          "id": "http://www.grid.ac/institutes/grid.424926.f", 
          "name": [
            "Royal Marsden Hospital, Sutton, Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Starling", 
        "givenName": "N", 
        "id": "sg:person.01136565472.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136565472.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "M-TAG Limited, Lee House, London, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "M-TAG Limited, Lee House, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tilden", 
        "givenName": "D", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Merck Pharmaceuticals, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Merck Pharmaceuticals, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "White", 
        "givenName": "J", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Royal Marsden Hosptal, Sutton, Surrey, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Royal Marsden Hosptal, Sutton, Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cunningham", 
        "givenName": "D", 
        "id": "sg:person.01320161130.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320161130.16"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2007-01-23", 
    "datePublishedReg": "2007-01-23", 
    "description": "The treatment of colorectal cancer is rapidly becoming a significant financial burden to health-care systems within economically developed nations. A current challenge for oncologists and health-care payers is to integrate new, often high-cost, biologic therapies into clinical practice. Inherent to this process is the consideration of cost-effectiveness. The aim of this study was to compare the cost-effectiveness of cetuximab plus irinotecan with an appropriate comparator from a National Health Service (NHS) perspective. This economic evaluation is a trial-based study of cetuximab vs active/best supportive care. Effectiveness estimates for the treatment groups were modelled from key clinical trials. Cunningham et al (2004) compared cetuximab/irinotecan with cetuximab monotherapy; Cunningham et al (1998) compared irinotecan monotherapy in a second-line setting with supportive care. Modelling was necessary owing to an absence of head-to-head clinical trial data of cetuximab/irinotecan vs current standard care. Costs were calculated for the study drugs received, associated administration, palliative chemotherapy for patients in the standard care arm and other nonchemotherapy resources. The discounted life-expectancy of patients treated with cetuximab/irinotecan was 0.91 life-years, and 0.47 discounted life-years for patients receiving active/best supportive care. Patients treated with cetuximab/irinotecan accumulated mean additional costs of \u00a318\u2009901 per patient relative to the comparator arm, with \u00a311\u2009802 attributable to cetuximab. The incremental cost per life-year gained with cetuximab/irinotecan therapy compared with active/best supportive care was \u00a342\u2009975. The incremental cost per quality adjusted life-year gained was \u00a357\u2009608. The incremental cost per life-year gained for cetuximab/irinotecan is relatively high compared with other health-care interventions. However, this result should be considered in the context of a number of factors specific to the treated patient population.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/sj.bjc.6603561", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "96"
      }
    ], 
    "keywords": [
      "best supportive care", 
      "cetuximab/irinotecan", 
      "supportive care", 
      "incremental cost", 
      "head clinical trial data", 
      "metastatic colorectal cancer patients", 
      "National Health Service perspective", 
      "standard care arm", 
      "key clinical trials", 
      "current standard care", 
      "colorectal cancer patients", 
      "previous chemotherapy treatment", 
      "absence of head", 
      "Health Service perspective", 
      "clinical trial data", 
      "health care payers", 
      "health care interventions", 
      "trial-based studies", 
      "significant financial burden", 
      "cost-effectiveness analysis", 
      "health care system", 
      "cetuximab monotherapy", 
      "palliative chemotherapy", 
      "care arm", 
      "study drug", 
      "biologic therapy", 
      "standard care", 
      "irinotecan therapy", 
      "irinotecan monotherapy", 
      "comparator arm", 
      "colorectal cancer", 
      "patient population", 
      "cancer patients", 
      "chemotherapy treatment", 
      "clinical trials", 
      "cetuximab/", 
      "treatment groups", 
      "patients", 
      "clinical practice", 
      "irinotecan", 
      "trial data", 
      "cetuximab", 
      "care", 
      "effectiveness estimates", 
      "financial burden", 
      "monotherapy", 
      "associated administration", 
      "appropriate comparator", 
      "therapy", 
      "treatment", 
      "economic evaluation", 
      "service perspective", 
      "Cunningham et al", 
      "chemotherapy", 
      "oncologists", 
      "arm", 
      "necessary owing", 
      "cancer", 
      "administration", 
      "trials", 
      "number of factors", 
      "drugs", 
      "intervention", 
      "burden", 
      "payers", 
      "study", 
      "additional cost", 
      "group", 
      "aim", 
      "population", 
      "head", 
      "factors", 
      "absence", 
      "comparator", 
      "evaluation", 
      "current challenges", 
      "practice", 
      "data", 
      "quality", 
      "number", 
      "analysis", 
      "cost", 
      "et al", 
      "results", 
      "challenges", 
      "consideration", 
      "owing", 
      "Vs", 
      "estimates", 
      "perspective", 
      "system", 
      "context", 
      "process", 
      "resources", 
      "nations", 
      "al", 
      "modelling"
    ], 
    "name": "Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment", 
    "pagination": "206-212", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1028751386"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.bjc.6603561"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "17242694"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.bjc.6603561", 
      "https://app.dimensions.ai/details/publication/pub.1028751386"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:34", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_447.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/sj.bjc.6603561"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6603561'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6603561'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6603561'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6603561'


 

This table displays all metadata directly associated to this object as RDF triples.

236 TRIPLES      20 PREDICATES      135 URIs      126 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.bjc.6603561 schema:about N03ae2a92154e48f4bc084c67d16df51a
2 N275423cfd8f54bedbee434625fe7e620
3 N47c336fa1c1845b397cc4caa4f604bbb
4 N53d65938e4f242efa63fe8cbc079b1c6
5 N5c70076c8b3749a7be6846dd385c495f
6 N73f9476051c448728aff18ca1673469b
7 Nb534147856c343a0832290d4e0467e7d
8 Nb560900663fe453bbfaecf29ca1e659e
9 Nce6d4a85b3024e408e7cd1e27df9a3ae
10 Ne3b12401d8464587b3c964b02daf868c
11 Nf727834de765457c805420a19fef11e9
12 Nf9054f64ba04459cba24f48e8276ff9a
13 anzsrc-for:11
14 anzsrc-for:1112
15 anzsrc-for:1117
16 schema:author N0b99a6a9ed66442c81bdcaf2c4fed530
17 schema:datePublished 2007-01-23
18 schema:datePublishedReg 2007-01-23
19 schema:description The treatment of colorectal cancer is rapidly becoming a significant financial burden to health-care systems within economically developed nations. A current challenge for oncologists and health-care payers is to integrate new, often high-cost, biologic therapies into clinical practice. Inherent to this process is the consideration of cost-effectiveness. The aim of this study was to compare the cost-effectiveness of cetuximab plus irinotecan with an appropriate comparator from a National Health Service (NHS) perspective. This economic evaluation is a trial-based study of cetuximab vs active/best supportive care. Effectiveness estimates for the treatment groups were modelled from key clinical trials. Cunningham et al (2004) compared cetuximab/irinotecan with cetuximab monotherapy; Cunningham et al (1998) compared irinotecan monotherapy in a second-line setting with supportive care. Modelling was necessary owing to an absence of head-to-head clinical trial data of cetuximab/irinotecan vs current standard care. Costs were calculated for the study drugs received, associated administration, palliative chemotherapy for patients in the standard care arm and other nonchemotherapy resources. The discounted life-expectancy of patients treated with cetuximab/irinotecan was 0.91 life-years, and 0.47 discounted life-years for patients receiving active/best supportive care. Patients treated with cetuximab/irinotecan accumulated mean additional costs of £18 901 per patient relative to the comparator arm, with £11 802 attributable to cetuximab. The incremental cost per life-year gained with cetuximab/irinotecan therapy compared with active/best supportive care was £42 975. The incremental cost per quality adjusted life-year gained was £57 608. The incremental cost per life-year gained for cetuximab/irinotecan is relatively high compared with other health-care interventions. However, this result should be considered in the context of a number of factors specific to the treated patient population.
20 schema:genre article
21 schema:isAccessibleForFree true
22 schema:isPartOf N19bdb1b1bc97465ea54d989b76e5f8ca
23 Nd04f2ae7abd74cb2b8358dda981c4c84
24 sg:journal.1017082
25 schema:keywords Cunningham et al
26 Health Service perspective
27 National Health Service perspective
28 Vs
29 absence
30 absence of head
31 additional cost
32 administration
33 aim
34 al
35 analysis
36 appropriate comparator
37 arm
38 associated administration
39 best supportive care
40 biologic therapy
41 burden
42 cancer
43 cancer patients
44 care
45 care arm
46 cetuximab
47 cetuximab monotherapy
48 cetuximab/
49 cetuximab/irinotecan
50 challenges
51 chemotherapy
52 chemotherapy treatment
53 clinical practice
54 clinical trial data
55 clinical trials
56 colorectal cancer
57 colorectal cancer patients
58 comparator
59 comparator arm
60 consideration
61 context
62 cost
63 cost-effectiveness analysis
64 current challenges
65 current standard care
66 data
67 drugs
68 economic evaluation
69 effectiveness estimates
70 estimates
71 et al
72 evaluation
73 factors
74 financial burden
75 group
76 head
77 head clinical trial data
78 health care interventions
79 health care payers
80 health care system
81 incremental cost
82 intervention
83 irinotecan
84 irinotecan monotherapy
85 irinotecan therapy
86 key clinical trials
87 metastatic colorectal cancer patients
88 modelling
89 monotherapy
90 nations
91 necessary owing
92 number
93 number of factors
94 oncologists
95 owing
96 palliative chemotherapy
97 patient population
98 patients
99 payers
100 perspective
101 population
102 practice
103 previous chemotherapy treatment
104 process
105 quality
106 resources
107 results
108 service perspective
109 significant financial burden
110 standard care
111 standard care arm
112 study
113 study drug
114 supportive care
115 system
116 therapy
117 treatment
118 treatment groups
119 trial data
120 trial-based studies
121 trials
122 schema:name Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment
123 schema:pagination 206-212
124 schema:productId N01d3680edcda4a8d8b93898d71206cc1
125 Nc57c23f865204598a062e5d3881ae943
126 Nda740896c8b8473181cd2ecf3ced32ef
127 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028751386
128 https://doi.org/10.1038/sj.bjc.6603561
129 schema:sdDatePublished 2022-10-01T06:34
130 schema:sdLicense https://scigraph.springernature.com/explorer/license/
131 schema:sdPublisher N86cd8779e9c14981959e0972aeb12db0
132 schema:url https://doi.org/10.1038/sj.bjc.6603561
133 sgo:license sg:explorer/license/
134 sgo:sdDataset articles
135 rdf:type schema:ScholarlyArticle
136 N01d3680edcda4a8d8b93898d71206cc1 schema:name doi
137 schema:value 10.1038/sj.bjc.6603561
138 rdf:type schema:PropertyValue
139 N03ae2a92154e48f4bc084c67d16df51a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Antineoplastic Combined Chemotherapy Protocols
141 rdf:type schema:DefinedTerm
142 N0b99a6a9ed66442c81bdcaf2c4fed530 rdf:first sg:person.01136565472.17
143 rdf:rest N6980b66a7cd84bf480750b5c8d0bf306
144 N19bdb1b1bc97465ea54d989b76e5f8ca schema:issueNumber 2
145 rdf:type schema:PublicationIssue
146 N275423cfd8f54bedbee434625fe7e620 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Humans
148 rdf:type schema:DefinedTerm
149 N38da62ffd84f4db198dfe2a8cd17b34a rdf:first Nc57dff71927f445799ab7ac4d7a97b81
150 rdf:rest N97807d65156141ffa0947aff3298007f
151 N47c336fa1c1845b397cc4caa4f604bbb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Colorectal Neoplasms
153 rdf:type schema:DefinedTerm
154 N53d65938e4f242efa63fe8cbc079b1c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Camptothecin
156 rdf:type schema:DefinedTerm
157 N5c70076c8b3749a7be6846dd385c495f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Cost-Benefit Analysis
159 rdf:type schema:DefinedTerm
160 N6980b66a7cd84bf480750b5c8d0bf306 rdf:first N7fd13230515c49bbb1ad53e782883b15
161 rdf:rest N38da62ffd84f4db198dfe2a8cd17b34a
162 N73f9476051c448728aff18ca1673469b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Neoplasm Metastasis
164 rdf:type schema:DefinedTerm
165 N7fd13230515c49bbb1ad53e782883b15 schema:affiliation grid-institutes:None
166 schema:familyName Tilden
167 schema:givenName D
168 rdf:type schema:Person
169 N86cd8779e9c14981959e0972aeb12db0 schema:name Springer Nature - SN SciGraph project
170 rdf:type schema:Organization
171 N97807d65156141ffa0947aff3298007f rdf:first sg:person.01320161130.16
172 rdf:rest rdf:nil
173 Nb534147856c343a0832290d4e0467e7d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Salvage Therapy
175 rdf:type schema:DefinedTerm
176 Nb560900663fe453bbfaecf29ca1e659e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Irinotecan
178 rdf:type schema:DefinedTerm
179 Nc57c23f865204598a062e5d3881ae943 schema:name pubmed_id
180 schema:value 17242694
181 rdf:type schema:PropertyValue
182 Nc57dff71927f445799ab7ac4d7a97b81 schema:affiliation grid-institutes:None
183 schema:familyName White
184 schema:givenName J
185 rdf:type schema:Person
186 Nce6d4a85b3024e408e7cd1e27df9a3ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Survival Analysis
188 rdf:type schema:DefinedTerm
189 Nd04f2ae7abd74cb2b8358dda981c4c84 schema:volumeNumber 96
190 rdf:type schema:PublicationVolume
191 Nda740896c8b8473181cd2ecf3ced32ef schema:name dimensions_id
192 schema:value pub.1028751386
193 rdf:type schema:PropertyValue
194 Ne3b12401d8464587b3c964b02daf868c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Cetuximab
196 rdf:type schema:DefinedTerm
197 Nf727834de765457c805420a19fef11e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Antibodies, Monoclonal, Humanized
199 rdf:type schema:DefinedTerm
200 Nf9054f64ba04459cba24f48e8276ff9a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Antibodies, Monoclonal
202 rdf:type schema:DefinedTerm
203 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
204 schema:name Medical and Health Sciences
205 rdf:type schema:DefinedTerm
206 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
207 schema:name Oncology and Carcinogenesis
208 rdf:type schema:DefinedTerm
209 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
210 schema:name Public Health and Health Services
211 rdf:type schema:DefinedTerm
212 sg:journal.1017082 schema:issn 0007-0920
213 1532-1827
214 schema:name British Journal of Cancer
215 schema:publisher Springer Nature
216 rdf:type schema:Periodical
217 sg:person.01136565472.17 schema:affiliation grid-institutes:grid.424926.f
218 schema:familyName Starling
219 schema:givenName N
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136565472.17
221 rdf:type schema:Person
222 sg:person.01320161130.16 schema:affiliation grid-institutes:None
223 schema:familyName Cunningham
224 schema:givenName D
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320161130.16
226 rdf:type schema:Person
227 grid-institutes:None schema:alternateName M-TAG Limited, Lee House, London, UK
228 Merck Pharmaceuticals, UK
229 Royal Marsden Hosptal, Sutton, Surrey, UK
230 schema:name M-TAG Limited, Lee House, London, UK
231 Merck Pharmaceuticals, UK
232 Royal Marsden Hosptal, Sutton, Surrey, UK
233 rdf:type schema:Organization
234 grid-institutes:grid.424926.f schema:alternateName Royal Marsden Hospital, Sutton, Surrey, UK
235 schema:name Royal Marsden Hospital, Sutton, Surrey, UK
236 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...